TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05940129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Women and Child, Safety, Health and Empowerment (WC-SHE)
Description: The WC-SHE component includes a risk assessment and tailored safety planning for women in domestic violence relationships. In addition, the component involves one-on-one education with husbands and in-laws. The economic empowerment component is designed to support women and their husbands in economic empowerment activities. The advocacy arm involves community education of husbands and in-laws, advocacy support by a support committee comprised of multidisciplinary professionals and phone support by women community resource persons

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Women and Child, Safety, Health and Empowerment (WC-SHE)
Description: The WC-SHE component includes a risk assessment and tailored safety planning for women in domestic violence relationships. In addition, the component involves one-on-one education with husbands and in-laws. The economic empowerment component is designed to support women and their husbands in economic empowerment activities. The advocacy arm involves community education of husbands and in-laws, advocacy support by a support committee comprised of multidisciplinary professionals and phone support by women community resource persons

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Women and Child, Safety, Health and Empowerment (WC-SHE)
Description: The WC-SHE component includes a risk assessment and tailored safety planning for women in domestic violence relationships. In addition, the component involves one-on-one education with husbands and in-laws. The economic empowerment component is designed to support women and their husbands in economic empowerment activities. The advocacy arm involves community education of husbands and in-laws, advocacy support by a support committee comprised of multidisciplinary professionals and phone support by women community resource persons
Study: NCT06197113

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magstim Rapid2 Magnetic Stimulator
Description: For TMS, the Magstim Rapid2 Magnetic Stimulator (Magstim, Whitland, Dyfed, UK) device, available in our center, was used.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Magstim Rapid2 Magnetic Stimulator
Description: For TMS, the Magstim Rapid2 Magnetic Stimulator (Magstim, Whitland, Dyfed, UK) device, available in our center, was used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magstim Rapid2 Magnetic Stimulator
Description: For TMS, the Magstim Rapid2 Magnetic Stimulator (Magstim, Whitland, Dyfed, UK) device, available in our center, was used.
Study: NCT05288387

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Description: High-frequency stimulation with modulated current via skin patches captures posterior horns of the spinal cord and this activation leads to blood pressure elevation.
Study: NCT06224335

Intervention type: DIAGNOSTIC_TEST
Intervention: intra-abdominal pressure with Femfit® device during (jumps on the ground, jumps on a trampoline, weightlifting, slow running, fast running
Description: Change in intravaginal and intra-abdominal pressure assessed by Femfit® , leakage of urine in grams assessed by inovative pad test during 5 sports activities.

Intervention type: DIAGNOSTIC_TEST
Intervention: intra-abdominal pressure with Femfit® device during (jumps on the ground, jumps on a trampoline, weightlifting, slow running, fast running
Description: Change in intravaginal and intra-abdominal pressure assessed by Femfit® , leakage of urine in grams assessed by inovative pad test during 5 sports activities.
Study: NCT06128291

Intervention type: PROCEDURE
Intervention: posterior colporrhaphy
Description: posterior colporrhaphy for rectocele.
Study: NCT06202625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avatrombopag
Description: The avatrombopag 20mg/d will be orally taken from +D7 after haplo-HSCT until meeting the adjustment indication or to +D60 after haplo-HSCT; When PLT\<50×10\^9/L or PLT transfusion-dependent on the +D30 after haplo-HSCT, increase avatrombopag dosage to 40 mg/d; When PLT≥80×10\^9/L and without PLT transfusion within avatrombopag dosage at 40 mg/d, decrease avatrombopag dosage to 20 mg/d; When PLT≥80×10\^9/L for 7 consecutive days or PLT≥300×10\^9/L and without PLT transfusion, stop avatrombopag; When PLT\<50×10\^9/L or PLT transfusion-dependent after stopping avatrombopag , reuse avatrombopag at 40 mg/d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo 20mg/d will be orally taken from +D7 after haplo-HSCT until meeting the adjustment indication or to +D60 after haplo-HSCT; When PLT\<50×10\^9/L or PLT transfusion-dependent on the +D30 after haplo-HSCT, increase placebo dosage to 40 mg/d; When PLT≥80×10\^9/L and without PLT transfusion within placebo dosage at 40 mg/d, decrease placebo dosage to 20 mg/d; When PLT≥80×10\^9/L for 7 consecutive days or PLT≥300×10\^9/L and without PLT transfusion, stop placebo; When PLT\<50×10\^9/L or PLT transfusion-dependent after stopping placebo, reuse placebo at 40 mg/d.
Study: NCT06556277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metyrapone And Hydrocortisone
Description: Drug: Metyrapone 250 mg Oral Tablets~During one phase of the study: Metyrapone (pills of 250mg) on full stomach: Day 1 0-1-2, day 2 1-2-2, day 3 3-3-4 day 4 3-3-4 day 5 3-3-4 day 6 3-3-4 day 7 3-0-0~Drug: Hydrocortisone 19,9mg/12mg s.c., pulsatile with a flow rate of 10μl/s~Hydrocortisone will be delivered subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 6 in a total daily dose of 19.9mg and 12mg on day 7

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo 250 mg Tablets~During another phase of the study: identical looking placebo pills starting Day 1 During one phase of the study: Metyrapone (pills of 250mg) on full stomach: Day 1 0-1-2, day 2 1-2-2, day 3 3-3-4 day 4 3-3-4 day 5 3-3-4 day 6 3-3-4 day 7 3-0-0~Drug: Placebo (0,9% NaCl solution)~Placebo (0,9% NaCl solution) 19.9 mg/d subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 6 and 12mg on day 7
Study: NCT06187961

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAIC
Description: administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus cadonilimab
Description: lenvatinib (8mg, qd) plus cadonilimab (10mg/kg, q3w)
Study: NCT05060146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured medico-pharmaceutical collaboration
Description: Reconciliation of drug treatments; Writing of the prescription for discharge from hospital for the pneumococcal vaccine; Pharmaceutical interview at discharge; Drafting of the discharge letter and transmission to the attending physician; Writing of the pharmaceutical discharge letter and transmission to the pharmacist; Pharmaceutical dispensing in the pharmacy; Administration of the vaccine by the attending physician or a nurse at home.
Study: NCT05220566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reserved Therapeutic Space
Description: The main objective of the 'Reserved Therapeutic Space' intervention is to enhance the therapeutic bond of trust, to enable the agreement of objectives and interventions in a shared manner in relation to their recovery process in the unit. The intervention is carried out through individual meetings between the nurse and the patient in a comfortable and intimate space, where there are no interruptions and which is also chosen by the person who is hospitalized. The content of the spaces must be constructed individually according to the patients' concerns at each moment of the process.
Study: NCT06161831

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message/automated phone reminder
Description: Receipt of text message or automated phone reminders notifying when the next HPV vaccine dose is due (either first or second)
Study: NCT05657613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYP450 Cocktail and Transporter Substrates with Pacritinib
Description: Day 1: Single oral dose of a cocktail of cytochrome P450 substrates (caffeine 100 mg, midazolam 2 mg, omeprazole 20 mg and metformin (transporter)~Day 3: Single oral dose of transporter substrates (digoxin 0.25 mg, rosuvastatin 5 mg)~Days 8-22: Oral doses of pacritinib 200 mg BID approximately 12 hours apart~Day 17: Single oral dose of transporter substrates (digoxin 0.25 mg and rosuvastatin 5 mg) will be coadministered with the AM dose of pacritinib 200 mg.~Day 21: Single oral dose of a cocktail of cytochrome P450 substrates (caffeine 100 mg, midazolam 2 mg, and omeprazole 20 mg) along with transporter substrate (metformin 500 mg) will be coadministered with the AM dose of pacritinib 200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib
Description: Days 1-7: Oral doses of pacritinib 200 mg BID~Days 8-14: Oral doses of pacritinib 200 mg BID, coadministered with an oral dose of bosentan 125 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib
Description: Days 1-7: Oral doses of pacritinib 200 mg BID~Days 8-14: Oral doses of pacritinib 200 mg BID, coadministered with an oral dose of fluconazole 200 mg QD.
Study: NCT05683886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KC1036
Description: Patients take 60mg QD of KC1036 for the efficacy and safety study. KC1036 are given orally once daily, 21 days as a cycle.
Study: NCT04721132

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT04801784

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Increased net ultrafiltration with advanced hemodynamic monitoring
Description: A net ultrafiltration rate of 100 ml/h or more will be applied during the first 72 hours of study participation. To insure the hemodynamic security of the intervention, it is associated with an advanced hemodynamic monitoring protocol which encompasses cardiac index, preload dependence assessment (using postural maneuvers), lactate levels and central venous pressure evaluation. The hemodynamic monitoring protocol allows the decrease or suspension of the neutral ultrafiltration rate in case of hemodynamic instability or of hemodynamic status considered at risk of worsening if net ultrafiltration rate is maintained.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Zero or near-zero net ultrafiltration
Description: The active control group aims to represent the present standard of care of net ultrafiltration management in the first 72 hours of study participation in patients with critical illness. This will be performed by setting the net ultrafiltration rate to 0 up to 25 ml/h.
Study: NCT04373356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resin Infiltration
Description: Patients will be instructed about enhancing their oral hygiene, and will be asked to brush their teeth twice a day with fluoride toothpaste, and use dental floss daily. In short, teeth will be isolated with a rubber dam and ICON will be applied following the manufacturer's instructions. After that, the rubber dam will be removed and 5% NaF Varnish will be applied.~Standardized digital bitewing radiograph will be taken at baseline and one year after treatment for caries lesion progression comparison.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Fluoride Varnish
Description: Patients will be instructed about enhancing their oral hygiene, and will be asked to brush their teeth twice a day with fluoride toothpaste, and use dental floss daily. In short, teeth will be isolated with cotton roll and 5% NaF varnish will be applied following the manufacturer's instructions.~Standardized digital bitewing radiograph will be taken at baseline and one year after treatment for caries lesion progression comparison.
Study: NCT06138834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose Y-6 sublingual tablets
Description: Take one Y-6 sublingual tablet (each tablet contains 25 mg Cilostazol and 6 mg Dexborneol), one placebo of Y-6 sublingual tablet (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), and two halves Cilostazol mimicry tablets (each tablet contains 0 mg Cilostazol) for 28 days continuously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose Y-6 sublingual tablets
Description: Take two Y-6 sublingual tablets (each tablet contains 25 mg Cilostazol and 6 mg Dexborneol), and two halves Cilostazol mimicry tablets (each tablet contains 0 mg Cilostazol) for 28 days continuously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose Cilostazol
Description: Take two tablets of placebo of Y-6 sublingual tablets (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), one half Cilostazol tablet (each tablet contains 50 mg Cilostazol), and one half Cilostazol mimicry tablet(each tablet contains 0 mg Cilostazol) for 28 days continuously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose Cilostazol
Description: Take two tablets of placebo of Y-6 sublingual tablets (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), and two halves Cilostazol tablet (each tablet contains 50 mg Cilostazol) for 28 days continuously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take two tablets of placebo of Y-6 sublingual tablets (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), and two halves Cilostazol mimicry tablets (each tablet contains 0 mg Cilostazol) for 28 days continuously.
Study: NCT06647316

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: The subjects will receive the first physiotherapy session : early mobilization, postural and joint ergonomics, sensory stimulation, temporal-spatial orientation and health education for the patient and the main caregiver are carried out.The plan will progress with postural control in a seated position, head and trunk control, re-education of transfers, balance, standing and walking, depending on the subject's abilities.The second physical therapy session incorporates taste and preference-based elements into the therapy itself. The third physiotherapy session is planned to take place in the physiotherapy unit. Following the individualized session, group interaction is encouraged, whether with other patients, the rehabilitation team and/or the patient's primary caregiver.In the fourth physiotherapy session, it is promoted therapeutic compliance.
Study: NCT06646913

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Patients will utilize the TENS device for 45 minutes, two times per day for the 4 week treatment period.
Study: NCT06646497

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation Stem cell source only Bone Marrow
Description: 1. Conditioning regimen Thymoglobulin (0.5/mg/kg à D-9, 2 mg /kg at D-8 and 2.5 mg/kg à D-7), Fludarabine (30mg/m2/day i.v: day -6 to day -2), pre-transplant, Cyclophosphamide (14.5 mg/kg/day i.v: day -6 and day -5), and Total Body Irradiation (2 Gray on day -1).~2. Stem cell source Bone Marrow only. Target of 4 × 10\^8 nucleated cells/kg recipient body weight. Granulocyte colony stimulating factor is given subcutaneously starting on day +5 at 5 mg/ kg/day until the absolute neutrophil count is greater than 1.5 × 10\^9/L for 3 days.~3. GVHD prophylaxis Cyclophosphamide 50 mg/Kg/day at D+3 and D+4. Tacrolimus (0,2 à 0,3 mg/kg/day per os divided into 2 doses or 0.05 to 0.1 mg/kg/d IVSE) and mycophenolate (MMF) will begin from D+5. In absence of GvHD, MMF will be stopped between D35 and D45 and Tacrolimus at day 365.~4. Prevention of EBV reactivation Rituximab 150mg/m2 intravenously at Day+5 post HSCT (except patients and their donor with EBV serology and EBV PCR negative).
Study: NCT06585748

Intervention type: DRUG
Intervention: Lidocaine spray
Description: 4 puffs of lidocaine spray was applied to the glans penis and urethral meatus, and after 5 minutes, the appropriate method and sterilization were used to apply a catheter gel, and a Foley catheter was placed in the bladder. After bladder catheterization, pain scores were evaluated by a neutral emergency medicine physician at 0 minutes (during the procedure), and at 15, 30, and 60 minutes post-procedure. The Face Legs Arms Cry Consolability Pain Scale (FLACC) and Wong-Baker pain scales were used for this evaluation.

Intervention type: OTHER
Intervention: Placebo
Description: No medication/application will be administered as placebo.
Study: NCT05123144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BHS+ORCHID
Description: At the clinic level, sites randomized to implement BHS+ORCHID will receive training, materials, and other support to administer behavioral health screening and refer their clients with elevated depression symptoms to ORCHID.~At the individual level, those clients who are eligible and choose to enroll in ORCHID will receive self-guided training on 8 positive affect skills through weekly online sessions and daily practice exercises.
Study: NCT05708677

Intervention type: BIOLOGICAL
Intervention: EB-101
Description: This is non-interventional and follows patients treated with EB-101
Study: NCT04727034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam tosylate
Description: Remazolam tosylate is an ultra-short-acting benzodiazepine drug, which has a mild inhibitory effect on the respiratory and circulatory systems and has anterograde amnesia. These advantages make remazolam tosylate very likely to replace propofol in painless gastroscopic anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam tosylate
Description: Remazolam tosylate is an ultra-short-acting benzodiazepine drug, which has a mild inhibitory effect on the respiratory and circulatory systems and has anterograde amnesia. These advantages make remazolam tosylate very likely to replace propofol in painless gastroscopic anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol is the most commonly used intravenous anesthetic for painless gastroscopy, but propofol significantly inhibits the respiratory and circulatory systems. Therefore, the incidence of intraoperative hypoxemia and hypotension is high.
Study: NCT05768321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEC255 tablets
Description: Part 1: Dose escalation After initial starting dose cohort, daily dosages in subsequent cohorts are determined by cohort review committee.~Part 2: Dose expansion Daily oral dosage RP2D based on data from Part 1
Study: NCT05240664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Have A Say Programme
Description: Each dyad of participants will receive a 4-session ACP programme, which consists of 2 group-based sessions and 2 dyadic sessions, one hour for each session. The group-based sessions are led by nurse which include didactic educational components, guided reflection, videos, and group sharing. Dyads of participants will be provided with information about ACP, the trajectory of dementia, their future healthcare needs and caring options. Their values and care preferences on future care will be elicited in a consistent manner. The dyadic sessions are facilitated by trained ACP facilitators and guided by an ACP booklet. Dyads of participants will be supported to have an individualized ACP discussion guided by an ACP booklet. By the end of the programme, each dyad of participants will be given an ACP booklet documenting the ACP process.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention-control health talks
Description: Dyads of participants in the control group will receive 4-session health talks. One hour for each session, and once weekly. The contents of the health talks are neither dementia-specific nor related to ACP, and cover general health information for elderly, such as drug safety, home safety, exercise and health, and healthy diet.
Study: NCT05358964

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: African American Family Health History Education Program
Description: The AAFHHEP arm is an intervention to increase utilization of FHH and increase preventative screening. This tool will be culturally tailored by African Americans for African Americans.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: African American Family Health History Education Program
Description: The AAFHHEP arm is an intervention to increase utilization of FHH and increase preventative screening. This tool will be culturally tailored by African Americans for African Americans.